Broad­en­ing its on­col­o­gy fo­cus, In­novent adds three In­cyte drugs to port­fo­lio for $40M cash

Buoyed by promis­ing Phase III da­ta on its PD-1 part­nered with Eli Lil­ly $LLY, In­novent Bi­o­log­ics is mak­ing an­oth­er ap­pear­ance on the glob­al deal­mak­ing scene — this time with In­cyte $IN­CY.

In­novent is bet­ting on three dis­tinct can­di­dates in In­cyte’s pipeline: itac­i­tinib (JAK1 in­hibitor), pemi­ga­tinib (FGFR1/2/3 in­hibitor) and parsaclis­ib (PI3Kδ in­hibitor). Itac­i­tinib is a Phase III treat­ment for graft-ver­sus-host dis­ease, where­as the oth­er two are un­der­go­ing mid-stage stud­ies. In­novent bagged the Chi­na rights to all three as­sets for $40 mil­lion in cash.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER